A Phase 2 Adult Angelman Syndrome Clinical Trial: A Randomized, Double-Blind, Safety and Efficacy Study of Gaboxadol
Phase of Trial: Phase II
Latest Information Update: 22 Sep 2017
At a glance
- Drugs Gaboxadol (Primary)
- Indications Angelman syndrome
- Focus Adverse reactions
- Acronyms STARS
- Sponsors Ovid Therapeutics
- 13 Jun 2017 According to an Ovid Therapeutics media release, the company expects topline data from the trial to be available in 2018.
- 09 Feb 2017 According to an Ovid Therapeutics media release, the first patient has been randomized in thsi trial.
- 03 Jan 2017 Status changed from not yet recruiting to recruiting.